The global Edward’s syndrome treatment market is set for significant growth, with a projected market value of USD 7.98 Billion by 2033, according to a newly released report. The market, valued at USD 4.9 Billion in 2023, is expected to grow at a Compound Annual Growth Rate (CAGR) of 5% from 2023 to 2033.
The growth of the Edward’s syndrome treatment market is largely attributed to increased investments in research and development, fueling the development of innovative treatment options. Historically, the market saw a CAGR of 3% from 2018 to 2022, highlighting the recent surge in progress and innovation in this space.
With more funding being funneled into genetic research and rare disease therapeutics, the Edward’s syndrome treatment market is poised to see continued advancement, offering improved care options for affected individuals.
Edwards syndrome, also known as Trisomy 18, is a chromosomal disorder that occurs in about 1 in 5,000 live births. The condition is characterized by severe intellectual disability and physical abnormalities, and many affected infants do not survive beyond the first few months of life.
It is possible that with the advancement of medical technology, doctors are now able to diagnose Edwards syndrome more accurately and earlier in pregnancy, which may lead to an increase in demand for treatment. Additionally, with the increasing popularity of genetic testing, more families may be learning about the diagnosis in their family, leading to more demand for treatment.
Market Competition
Key players in the Edwards syndrome treatment market are Merck & Co, Kyorin Pharmaceuticals, Pfizer Inc, Bellus Health, Eli Lilly and Company, GeneScience Pharmaceuticals Co., Ltd, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sanofi, Bayer AG
- Sanofi, a key player in the Edwards syndrome treatment market is focusing on integrating technology to offer diagnostic tests for treating Edwards syndrome treatment.
- Johnson & Johnson Private Limited, another key player in the Edwards syndrome treatment market is focusing on investing in research and development for innovating medications.
Key Companies Profiled
- Merck & Co
- Kyorin Pharmaceuticals
- Pfizer Inc
- Bellus Health
- Eli Lilly and Company
- GeneScience Pharmaceuticals Co., Ltd
- Johnson & Johnson Private Limited
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Bayer AG
Key Segments Profiled in the Edward’s Syndrome Treatment Industry Survey
Types:
- Full Trisomy 18
- Mosaic Trisomy 18
- Partial Trisomy 18
Treatment:
- Cardiac Treatment
- Assisted Feeding
- Orthopaedic Treatment
- Psychosocial Support
- Others
End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centres
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube